FOLLOWUS
Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方) in lung cancer drug-resistance cells
Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方) in lung cancer drug-resistance cells
- 中国结合医学杂志（英文版） 2008年14卷第1期 页码：46-50
- Affiliations：
Department of Traditional Chinese Medicine, Jinan University Medical School,Guangzhou,China
- Author bio：
- Funds：Supported by Post-Doctoral Foundation of China, (2001)5, Guangdong Province Technology Project (No. 73062)
DOI：10.1007/s11655-007-9004-4
中图分类号：纸质出版日期：2008，
网络出版日期：2008-6-21，
Scan for full text
Cao, Y., Xia, Qh., Meng, H. et al. Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方) in lung cancer drug-resistance cells., Chin. J. Integr. Med. 14, 46–50 (2008). https://doi.org/10.1007/s11655-007-9004-4
Yong Cao, Qing-hua Xia, Hua Meng, et al. Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方) in lung cancer drug-resistance cells[J]. Chinese Journal of Integrative Medicine, 2008,14(1):46-50.
Cao, Y., Xia, Qh., Meng, H. et al. Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方) in lung cancer drug-resistance cells., Chin. J. Integr. Med. 14, 46–50 (2008). https://doi.org/10.1007/s11655-007-9004-4 DOI：
Yong Cao, Qing-hua Xia, Hua Meng, et al. Pharmacological effects of serum containing chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方) in lung cancer drug-resistance cells[J]. Chinese Journal of Integrative Medicine, 2008,14(1):46-50. DOI： 10.1007/s11655-007-9004-4.
摘要
To explore the pharmacologic effects of Chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方
BSHYJDR) in drug-resistance cells of lung cancer. Human lung adenocarcinoma A549/DDP cell strain was selected
serum pharmacology and flow cytometer (FCM) method were adopted
S180 tumor-bearing mice and normal mice were given
through gastrogavage
different doses of a decocted concentration of BSHYJDR. Serum from the abdominal aorta was taken to observe the effect of drug-serum on cisplatin (DDP) concentration
free Ca2+ concentration and the expression of lung drug-resistance protein LRP-56 in A549/DDP cells. Compared with the drug-resistance group
the intracellular DDP concentration in the group taking a high dose and the normal group of Chinese medicine showed significant difference (P<0.05)
while no significant difference was found in the low-dose group (P>0.05). Compared with the drug-resistance group
the Ca2+ concentration in cells and the expression of LRP in lung cancer drug-resistance cells A549/DDP of the high-dose group
the low-dose group and the normal group of Chinese medicine were significantly different (all P<0.01)
the LRP expression of the normal group was obviously higher than that of the drug-resistance group (P<0.05). It was indicated that serum containing Chinese medicine BSHYJDR in the tumor-bearing mice and the normal mice had certainly different
tumor-bearing mice serum containing could improve drug concentration in lung cancer drug-resistance cells
prevent the inflow and release of Ca2+
and inhibit the expression of the drug-resistance gene in the lung cancer drug-resistance cells
which might be the mechanism of BSHYJDR in enhancing the efficacy in reversing and inhibiting tumor.
Abstract
To explore the pharmacologic effects of Chinese medicine Bushen Huayu Jiedu Compound Recipe (补肾化瘀解毒复方
BSHYJDR) in drug-resistance cells of lung cancer. Human lung adenocarcinoma A549/DDP cell strain was selected
serum pharmacology and flow cytometer (FCM) method were adopted
S180 tumor-bearing mice and normal mice were given
through gastrogavage
different doses of a decocted concentration of BSHYJDR. Serum from the abdominal aorta was taken to observe the effect of drug-serum on cisplatin (DDP) concentration
free Ca2+ concentration and the expression of lung drug-resistance protein LRP-56 in A549/DDP cells. Compared with the drug-resistance group
the intracellular DDP concentration in the group taking a high dose and the normal group of Chinese medicine showed significant difference (P<0.05)
while no significant difference was found in the low-dose group (P>0.05). Compared with the drug-resistance group
the Ca2+ concentration in cells and the expression of LRP in lung cancer drug-resistance cells A549/DDP of the high-dose group
the low-dose group and the normal group of Chinese medicine were significantly different (all P<0.01)
the LRP expression of the normal group was obviously higher than that of the drug-resistance group (P<0.05). It was indicated that serum containing Chinese medicine BSHYJDR in the tumor-bearing mice and the normal mice had certainly different
tumor-bearing mice serum containing could improve drug concentration in lung cancer drug-resistance cells
prevent the inflow and release of Ca2+
and inhibit the expression of the drug-resistance gene in the lung cancer drug-resistance cells
which might be the mechanism of BSHYJDR in enhancing the efficacy in reversing and inhibiting tumor.
关键词
serum containing Chinese compound medicinelung cancer drug-resistance cellcisplatin concentrationCa2+ concentrationlung drug-resistance protein expression
Keywords
serum containing Chinese compound medicinelung cancer drug-resistance cellcisplatin concentrationCa2+ concentrationlung drug-resistance protein expression
references
Oguri T, Isobe T, Suzuki T, et al. Increased expression MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 2000;86:95–100.
Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945–957.
Nygren P, Larsson R, Gruber A, et al. Doxorubicin selected multidrug-resistant small cell lung cancer cell lines characterised by elevated cytoplasmic Ca2+ and resistance modulation by verapamil in absence of P-glycoprotein overexpression. Br J Cancer 1991;64:1011–1018.
Obata NH, Okazaki K, Maeda O, et al. Effect of KN-62, Ca2+/calmoduln-dependent protein kinase II inhibitor, on adriamycin resistance of human ovarian cancer cells. Biochem Biophys Res Commun 1995;215:566–571.
Scheper RJ, Broxterman HJ, Scheffer GL, et al. Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res 1993;53:1475–1479.
Berger W, Elbing L, Micksche M, et al. Expression of the major vault protein LRP in human non-small-cell lung cancer cells activation by short-term exposure to antineoplastic drugs. Int J Cancer 2000;88:293–300.
Lu MJ, Wang J, Yi XH, et al. Clinical significance of the expression of lung resistance protein in non-small cell lung carcinomas. Chin J Tubercul Respir Dis (Chin) 2001; 24(8):458–460.
Ikda K, Oka M, Narasaki F, et al. Lung resistancerelated protein gene expression and drug sensitivity in human gastric and lung cancer cells. Anticancer Res 1998;18(4C):3077–3080.
0
浏览量
332
Downloads
8
CSCD
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
